Prostate cancer susceptibility genes: Many studies, many results, no answers

Cancer and Metastasis Reviews

Volumn 20, Issue 3-4, 2001, Pages 155-164

  Nupponen, Nina N ^a   Carpten, John D ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Hereditary; Mutation; Predisposition; Prostate cancer

Indexed keywords

CANCER SUSCEPTIBILITY; CHROMOSOMAL LOCALIZATION; CHROMOSOME 1; FAMILY HISTORY; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; MOLECULAR CLONING; PENETRANCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEGREGATION ANALYSIS;

CHROMOSOME MAPPING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS;

EID: 0035740243     PISSN: 01677659     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015557308033     Document Type: Review

References (99)

1. Family history and the risk of prostate cancer
2. Risk of cancer in relatives of prostate cancer probands
3. Hereditary prostate cancer: Epidemiologic and clinical features
4. Mendelian inheritance of familial prostate cancer
5. Evidence of an X-linked or recessive genetic component to prostate cancer risk
6. The impact of family history on early detection of prostate cancer
7. Evidence for autosomal dominant inheritance of prostate cancer
8. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search
9. Family history facilitates the early diagnosis of prostate carcinoma
10. Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
11. Re: Prostate cancer susceptibility locus on chromosome 1q: A confirmatory study
12. Linkage analysis of chromosome 1q markers in 136 prostate cancer families
13. Familial prostate cancer studies in Utah
14. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer
15. Combined analysis of hereditary prostate cancer linkage to 1q24-25: Results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics
16. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer
17. Linkage analysis of 150 high-risk prostate cancer families at 1q24-25
18. Linkage of prostate cancer susceptibility loci to chromosome 1
19. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci
20. A 6-Mb high-resolution physical and transcription map encompassing the hereditary prostate cancer 1 (HPC1) region
21. Cloning and characterization of 13 novel transcripts and the human rgs8 gene from the 1q25 region encompassing the hereditary prostate cancer (hpc1) locus
22. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43
23. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer
24. A genome screen of multiplex sibships with prostate cancer
25. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe
26. Model-free linkage analysis with covariates confirms linkage of prostate cancer to chromosomes 1 and 4
27. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36
28. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas
29. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype
30. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization
31. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers
32. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma
33. Mutation and expression analysis of the p73 gene in prostate cancer
34. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer
35. Evidence for a prostate cancer susceptibility locus on the X chromosome
36. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX
37. A genetic epidemiological study of hereditary prostate cancer (HPC) in Finland: Frequent HPCX linkage in families with late-onset disease
38. Genetic linkage analysis of prostate cancer families to Xq27-28
39. A genome screen of families with multiple cases of prostate cancer: Evidence of genetic heterogeneity
40. A candidate prostate cancer susceptibility gene at chromosome 17p
41. Association of HPC2/ELAC2 genotypes and prostate cancer
42. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer
43. Polymorphisms in the prostate cancer susceptibility gene HPC2/ELAC2 in multiplex families and health controls
44. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer
45. Role of HPC2/ELAC2 in hereditary prostate cancer
46. HPC2 variants and screen-detected prostate cancer
47. Germ-line BRCA1 mutations in selected men with prostate cancer
48. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
49. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer
50. High frequency of mutator phenotype in human prostatic adenocarcinoma
51. Localization of potential tumor suppressor loci to a <2 Mb region on chromosome 17q in human prostate cancer
52. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization
53. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
54. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma
55. Genetic alterations in hormone-refractory recurrent prostate carcinomas
56. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases
57. Evidence for a prostate cancer-susceptibility locus on chromosome 20
58. Analysis of the prostate cancer-susceptibility locus HPC20 in 172 families affected by prostate cancer
59. Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families
60. Genome-wide scan for prostate cancer-aggressiveness loci
61. Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers
62. Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: Identification of three independent regions
63. Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer
64. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer
65. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer
66. Cadherin switching in human prostate cancer progression
67. E-cadherin germline mutations in familial gastric cancer
68. Relatives of prostate cancer patients have an increased risk of prostate and stomach cancers: A population-based, cancer registry study in Finland
69. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes
70. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21
71. A genomic scan of families with prostate cancer identifies multiple regions of interest
72. Linkage and association studies of prostate cancer susceptibility: Evidence for linkage at 8p22-23
73. Genetic basis and clonal evolution of human prostate cancer
74. Tumour-suppressor genes in prostatic oncogenesis: A positional approach
75. Chromosomal basis of adenocarcinoma of the prostate
76. Molecular biology of progression of prostate cancer
77. Chromosomal clues to the development of prostate tumors
78. Androgen-receptor gene structure and function in prostate cancer
79. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
80. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
81. Molecular basis of androgen insensitivity
82. Mutated human androgen receptor gene detected in a prostatic cancer patient is also activated by estradiol
83. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia
84. Two percent of Finnish prostate cancer patients have a germ-line mutation in the hormone-binding domain of the androgen receptor gene
85. In vivo amplification of the androgen receptor gene and progression of human prostate cancer
86. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
87. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist
88. Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone
89. Unusual length polymorphism in human steroid 5 alpha-reductase type 2 gene (SRD5A2)
90. Genetic variability of the human SRD5A2 gene: Implications for prostate cancer risk
91. A prevalent missense substitution that modulates activity of prostatic steroid 5alpha-reductase
92. Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA
93. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2)
94. The role of steroid hormones in prostate carcinogenesis
95. Hormonal carcinogenesis
96. Recruitment experience in the first phase of the African American Hereditary Prostate Cancer (AAHPC) study